Hydromorphone Hydrochloride Kalceks (Hydromorphone Hydrochloride)

Hydromorphone Hydrochloride is an opioid analgesic indicated for conditions involving severe nociceptive pain.

• Severe acute pain: provides rapid, potent analgesia for patients with intense, short‑term pain.
• Postoperative pain: controls pain following surgical procedures when strong opioid therapy is required.
• Cancer‑related pain: alleviates persistent, severe pain associated with malignant disease.

• Hydromorphone Hydrochloride acts as a high‑affinity agonist at the μ‑opioid receptors in the central nervous system. Binding to these G‑protein‑coupled receptors inhibits adenylate cyclase activity, reduces calcium influx, and increases potassium efflux, leading to decreased neuronal excitability and suppression of pain signal transmission in the spinal cord and brain. The resultant analgesic effect is dose‑dependent and may be accompanied by typical opioid‑related central effects.

Hydromorphone Hydrochloride may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: sensation of queasiness often accompanied by vomiting.
• Constipation: reduced bowel movements and hard stools.
• Drowsiness: increased sleepiness or fatigue.
• Dizziness: feeling light‑headed or unsteady.
• Dry mouth: reduced salivation leading to oral discomfort.
• Sweating: excessive perspiration.
• Itching: mild skin pruritus.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing that can be life‑threatening.
• Severe hypotension: marked drop in blood pressure causing dizziness or fainting.
• Addiction or dependence: potential for misuse and physical dependence with prolonged use.
• Anaphylaxis: rare severe allergic reaction with rash, swelling, and airway compromise.
• Seizures: rare occurrence of convulsions.
• Hallucinations: visual or auditory disturbances.

When using Hydromorphone Hydrochloride, clinicians should observe several safety measures to minimize risk.

• Assess respiratory function: monitor breathing rate and oxygen saturation before and during therapy.
• Evaluate hepatic and renal function: adjust dosing in patients with liver or kidney impairment.
• Avoid concurrent CNS depressants: limit use with benzodiazepines, barbiturates, or alcohol to reduce additive sedation.
• Use caution in the elderly: increased sensitivity may require lower initial doses.
• Monitor for signs of dependence: watch for cravings, tolerance, or withdrawal symptoms.
• Store at room temperature: keep in original container, protect from moisture and light.

Hydromorphone Hydrochloride can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Other opioids: combined use can cause profound respiratory depression.
• Central nervous system depressants: benzodiazepines, anesthetics, or alcohol increase sedation risk.
• Monoamine oxidase inhibitors (MAOIs): may precipitate severe hypertension or serotonin syndrome.
• Respiratory depressants: muscle relaxants or antihistamines can exacerbate breathing suppression.
• CYP3A4 inhibitors: strong inhibitors can raise hydromorphone plasma levels.

Moderate Interactions (Monitor Closely)

• CYP2D6 inhibitors: may modestly increase drug exposure.
• Diuretics: may enhance hypotensive effects.
• Antihistamines: can add to sedation.
• Serotonergic agents: risk of serotonin syndrome when combined with high doses.
• Anticholinergics: may worsen constipation.